- Home
- TYRA vs WRLD Comparison
TYRA vs WRLD Comparison
Compare TYRA & WRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- WRLD
- Stock Information
- Founded
- TYRA 2018
- WRLD 1962
- Country
- TYRA United States
- WRLD United States
- Employees
- TYRA N/A
- WRLD N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- WRLD Finance: Consumer Services
- Sector
- TYRA Health Care
- WRLD Finance
- Exchange
- TYRA Nasdaq
- WRLD Nasdaq
- Market Cap
- TYRA 844.2M
- WRLD 683.3M
- IPO Year
- TYRA 2021
- WRLD 1991
- Fundamental
- Price
- TYRA $14.27
- WRLD $132.72
- Analyst Decision
- TYRA Strong Buy
- WRLD
- Analyst Count
- TYRA 5
- WRLD 0
- Target Price
- TYRA $31.20
- WRLD N/A
- AVG Volume (30 Days)
- TYRA 261.6K
- WRLD 68.0K
- Earning Date
- TYRA 11-05-2025
- WRLD 10-23-2025
- Dividend Yield
- TYRA N/A
- WRLD N/A
- EPS Growth
- TYRA N/A
- WRLD N/A
- EPS
- TYRA N/A
- WRLD 10.75
- Revenue
- TYRA N/A
- WRLD $570,763,378.00
- Revenue This Year
- TYRA N/A
- WRLD $0.89
- Revenue Next Year
- TYRA N/A
- WRLD $3.51
- P/E Ratio
- TYRA N/A
- WRLD $12.20
- Revenue Growth
- TYRA N/A
- WRLD 2.33
- 52 Week Low
- TYRA $6.42
- WRLD $104.99
- 52 Week High
- TYRA $17.78
- WRLD $185.48
- Technical
- Relative Strength Index (RSI)
- TYRA 49.37
- WRLD 33.22
- Support Level
- TYRA $13.35
- WRLD $129.24
- Resistance Level
- TYRA $15.38
- WRLD $135.36
- Average True Range (ATR)
- TYRA 0.92
- WRLD 7.56
- MACD
- TYRA -0.14
- WRLD -1.72
- Stochastic Oscillator
- TYRA 35.37
- WRLD 11.03
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About WRLD World Acceptance Corporation
World Acceptance Corp operates a small-loan consumer finance business. The company offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. It also offers income tax return preparation services to its loan customers and other individuals. The Company operates 1,024 branches in Alabama, Georgia, Idaho, Illinois, Indiana, Kentucky, Louisiana, Mississippi, Missouri, New Mexico, Oklahoma, South Carolina, Texas, Tennessee, Utah, and Wisconsin.